Clostridioides difficile Diagnosis and Treatment
Diagnosis
Use a two-step diagnostic algorithm combining glutamate dehydrogenase (GDH) or nucleic acid amplification test (NAAT) with toxin immunoassay to distinguish true infection from colonization 1, 2. Test only patients with acute diarrhea (≥3 unformed stools in 24 hours), particularly following antibiotic exposure. Do not test formed stools or asymptomatic patients.
Diagnostic Algorithm:
- Step 1: GDH enzyme immunoassay or NAAT (PCR) to detect organism presence
- Step 2: Toxin immunoassay to confirm active toxin production
- If discordant results (positive NAAT, negative toxin) with high clinical suspicion: treat the patient 2
Key pitfall: NAAT-only testing detects colonization, not necessarily active infection. Multistep testing prevents overdiagnosis and unnecessary treatment 3.
Disease Severity Classification
Classify all hospitalized patients at diagnosis 2:
- Mild-moderate: Diarrhea without systemic signs, WBC <15,000 cells/mL, creatinine <1.5× baseline
- Severe: WBC ≥15,000 cells/mL OR creatinine ≥1.5× baseline 4, 2
- Fulminant: Severe disease PLUS shock, ileus, or megacolon 2
Treatment
Initial Episode (Non-fulminant)
Fidaxomicin 200 mg orally twice daily for 10 days is the preferred first-line therapy due to lower recurrence rates 2, 5. Vancomycin 125 mg orally four times daily for 10 days is an acceptable alternative 1, 2.
Do not use metronidazole for initial or recurrent CDI except in fulminant disease when combined with vancomycin 2, 5. The 2018 IDSA/SHEA guidelines 1 and all recent expert reviews 2, 5 have moved away from metronidazole due to inferior outcomes.
Fulminant CDI
Requires multidisciplinary management (gastroenterology, surgery, critical care) with aggressive combination therapy 2:
- Vancomycin 500 mg orally/enterally every 6 hours
- PLUS metronidazole 500 mg IV every 8 hours
- PLUS vancomycin 500 mg per rectum every 6 hours if ileus present
Consider multi-dose fecal microbiota transplantation (FMT) via colonoscopy in fulminant cases 2. After recovery, maintain suppressive vancomycin until outpatient FMT can be administered to prevent recurrence.
First Recurrence (Second Episode)
Treat with either vancomycin taper (125 mg four times daily × 10-14 days, then taper) or fidaxomicin 200 mg twice daily for 10 days 1, 2. Assess recurrence risk factors: age >65, ongoing antibiotics, proton pump inhibitors, comorbidities, severe initial disease 4.
Second Recurrence (Third Episode)
Offer fecal microbiota-based therapy after completing antibiotic treatment 2, 5:
- FDA-approved options: fecal microbiota spores, live-brpk (Vowst) or fecal microbiota, live-jslm (Rebyota)
- Conventional FMT via colonoscopy remains effective, particularly for severe/fulminant disease 2
Consider microbiota restoration therapy earlier (after first recurrence or even initial episode) in high-risk patients or those with particularly morbid initial episodes 2.
Multiple Recurrences
For patients who fail or cannot receive microbiota-based therapies: prolonged suppressive vancomycin 125 mg daily may be used as secondary prophylaxis 2.
Critical Management Points
- Stop precipitating antibiotics immediately when CDI is suspected 4
- Do not perform test of cure after treatment completion; only retest if symptoms persist or worsen 2
- Do not use cholestyramine or bile acid binders concurrently with vancomycin or fidaxomicin 2
- Evaluate but do not automatically discontinue proton pump inhibitors if legitimate indication exists 2
- Do not use probiotics for CDI prevention or treatment 2
- Counsel patients to avoid unnecessary future antibiotics and consider home disinfection with sporicidal agents 2
The evidence strongly favors fidaxomicin over vancomycin for initial therapy due to lower recurrence rates, with metronidazole relegated to combination therapy in fulminant disease only. Early consideration of microbiota restoration therapy is increasingly important given high recurrence rates (20-30%) after standard antibiotic treatment 4, 2.